Pavel A. Shesternya
Krasnoyarsk, KYA, Russian Federation
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications
Guselkumab in Biologic-Naïve Patients with Active Psoriatic Arthritis in Russia: A Post Hoc Analysis of the DISCOVER-1 and -2 Randomized Clinical Trials.
Journal: Rheumatology and therapy
Published: June 05, 2024
Monitoring of breast cancer progression via aptamer-based detection of circulating tumor cells in clinical blood samples.
Journal: Frontiers in molecular biosciences
Published: March 11, 2023
Development of DNA aptamers for visualization of glial brain tumors and detection of circulating tumor cells.
Journal: Molecular therapy. Nucleic acids
Published: November 09, 2022
Features of Peripheral Blood Th-Cell Subset Composition and Serum Cytokine Level in Patients with Activity-Driven Ankylosing Spondylitis.
Journal: Pharmaceuticals (Basel, Switzerland)
Published: October 09, 2022
The Role of Single-Nucleotide Variants of NOS1, NOS2, and NOS3 Genes in the Comorbidity of Arterial Hypertension and Tension-Type Headache.
Journal: Molecules (Basel, Switzerland)
Published: February 16, 2021
Using Pharmacogenetics of Direct Oral Anticoagulants to Predict Changes in Their Pharmacokinetics and the Risk of Adverse Drug Reactions.
Journal: Biomedicines
Published: February 04, 2021
The efficacy and safety of intra-articular application of a combination of sodium hyaluronate and chondroitin sulfate for osteoarthritis of the knee: a multicenter prospective study
Journal: Terapevticheskii arkhiv
Published: June 04, 2020
Efficacy, pharmacokinetics and safety of subcutaneous versus intravenous CT-P13 in rheumatoid arthritis: a randomized phase I/III trial.
Journal: Rheumatology (Oxford, England)
Published: May 12, 2020
Long-Term Efficacy and Safety of Biosimilar CT-P10 Versus Innovator Rituximab in Rheumatoid Arthritis: 48-Week Results from a Randomized Phase III Trial.
Journal: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
Published: February 06, 2019
Efficacy and safety of switching from rituximab to biosimilar CT-P10 in rheumatoid arthritis: 72-week data from a randomized Phase 3 trial.
Journal: Rheumatology (Oxford, England)
Published: November 15, 2018
Primary efficacy of netakimab, a novel interleukin-17 inhibitor, in the treatment of active ankylosing spondylitis in adults.
Journal: Clinical and experimental rheumatology
Published: October 15, 2018
Comparison of biosimilar CT-P10 and innovator rituximab in patients with rheumatoid arthritis: a randomized controlled Phase 3 trial.
Journal: mAbs
Published: July 17, 2018
Last Updated: 09/26/2026